Fackler, Mary Jo
Pleas, Madison
Li, Youran
Soni, Anushri
Xing, Deyin
Cope, Leslie
Ali, Syed
Van Le, Quang
Van Nguyen, Chu
Pham, Han Thi
Duong, Long Minh
Vanden Berg, Eunice
Wadee, Reubina
Michelow, Pamela
Chen, Wenlong Carl
Joffe, Maureen
Fjeldbo, Christina Saetan
Lyng, Heidi
Sukumar, Saraswati http://orcid.org/0000-0002-5656-6703
Funding for this research was provided by:
The Rubenstein Family Fund (80014042, 80014042, 80014042, 80014042, 80014042, 80014042, 80014042, 80014042)
NCI Cervical Cancer Spore Program (P50CA 09852, P50CA 09852)
Article History
Received: 8 December 2023
Accepted: 4 April 2024
First Online: 20 April 2024
Declarations
:
: Tissues and cervical smears were obtained and tested following approval by The Johns Hopkins Institutional Review Board (Approval No. IRB00241118 / CIR00095880), Johns Hopkins Hospital, Baltimore, USA, the Ethics Review Board of National Health Laboratory Services (Approval No. M1911125), Johannesburg, S. Africa, and the Ethics Committee of the Vietnam Hanoi Medical University (Approval No. 4400/QD-DHYHN), Hanoi, Vietnam.
: Not applicable.
: S.S and M.J.F have the following issued patents: US8062849B2, US8822155B2, US9416404B2, US20140220561A1, US20150057188A1, and pending patent, 63/533,972. Royalty fees were received from Cepheid December 2014 through July 15, 2021, for use of JHU patents.